Put Antipsychotics for Agitation in Dementia in Perspective

September 2023

A new indication for brexpiprazole (Rexulti) will raise questions about treating agitation in dementia with antipsychotics.

Brexpiprazole is a second-generation antipsychotic already approved for schizophrenia and as an add-on for depression.

Now you’ll hear that brexpiprazole is the first med FDA-approved for agitation in patients with Alzheimer’s dementia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote